VRCA Stock Forecast 2025-2026
Distance to VRCA Price Targets
VRCA Price Momentum
10 Quality Stocks Worth Considering Now
Researching Verrica (VRCA) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on VRCA and similar high-potential opportunities.
Latest VRCA Stock Price Targets & Analyst Predictions
Based on our analysis of 9 Wall Street analysts, VRCA has a neutral consensus with a median price target of $3.00 (ranging from $2.00 to $5.00). The overall analyst rating is Buy (7.3/10). Currently trading at $0.54, the median forecast implies a 458.7% upside. This outlook is supported by 2 Buy, 4 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Gregory Renza at RBC Capital, suggesting a 272.4% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
VRCA Analyst Ratings
VRCA Price Target Range
Latest VRCA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for VRCA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 12, 2025 | Needham | Serge Belanger | Hold | Reiterates | $0.00 |
| Dec 20, 2024 | Needham | Serge Belanger | Hold | Reiterates | $0.00 |
| Nov 6, 2024 | HC Wainwright & Co. | Oren Livnat | Neutral | Downgrade | $0.00 |
| Nov 5, 2024 | Needham | Serge Belanger | Hold | Reiterates | $0.00 |
| Nov 5, 2024 | RBC Capital | Gregory Renza | Sector Perform | Downgrade | $2.00 |
| Oct 21, 2024 | TD Cowen | Stacy Ku | Buy | Maintains | $10.00 |
| Oct 4, 2024 | RBC Capital | Gregory Renza | Outperform | Maintains | $11.00 |
| Oct 3, 2024 | Needham | Serge Belanger | Hold | Downgrade | $12.00 |
| Oct 2, 2024 | Brookline Capital | Kemp Dolliver | Hold | Downgrade | $0.00 |
| Aug 15, 2024 | RBC Capital | Gregory Renza | Outperform | Maintains | $13.00 |
| Aug 15, 2024 | Needham | Serge Belanger | Buy | Maintains | $12.00 |
| May 16, 2024 | Needham | Serge Belanger | Buy | Reiterates | $16.00 |
| May 14, 2024 | HC Wainwright & Co. | Oren Livnat | Buy | Maintains | $14.00 |
| May 14, 2024 | Needham | Serge Belanger | Buy | Maintains | $16.00 |
| Apr 10, 2024 | Needham | Buy | Reiterates | $8.00 | |
| Mar 1, 2024 | Needham | Serge Belanger | Buy | Reiterates | $8.00 |
| Mar 1, 2024 | HC Wainwright & Co. | Oren Livnat | Buy | Maintains | $13.00 |
| Dec 15, 2023 | Jefferies | Glen Santangelo | Buy | Reiterates | $10.00 |
| Nov 10, 2023 | Needham | Serge Belanger | Buy | Maintains | $8.00 |
| Oct 12, 2023 | HC Wainwright & Co. | Oren Livnat | Buy | Reiterates | $12.00 |
Verrica Pharmaceuticals Inc. (VRCA) Competitors
The following stocks are similar to Verrica based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Verrica Pharmaceuticals Inc. (VRCA) Financial Data
Verrica Pharmaceuticals Inc. has a market capitalization of $49.31M with a P/E ratio of -0.4x. The company generates $7.57M in trailing twelve-month revenue with a 63.8% profit margin.
Revenue growth is -82.7% quarter-over-quarter, while maintaining an operating margin of -3,292.7% and return on equity of -1,546.6%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Verrica Pharmaceuticals Inc. (VRCA) Business Model
About Verrica Pharmaceuticals Inc.
Develops innovative treatments for skin diseases.
Verrica Pharmaceuticals operates in the pharmaceutical industry, focusing on niche dermatological products. The company generates revenue through the development and commercialization of its proprietary drug-device combination, VP-102, aimed at treating skin conditions that lack FDA-approved treatments, thereby addressing unmet medical needs in dermatology.
Verrica collaborates with dermatologists and healthcare providers to enhance patient care and improve treatment options for skin diseases, positioning itself strategically within a specialized market that larger pharmaceutical companies may overlook.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
71
CEO
Dr. Jayson M. Rieger M.B.A., Ph.D.
Country
United States
IPO Year
2018
Website
www.verrica.comVerrica Pharmaceuticals Inc. (VRCA) Latest News & Analysis
Verrica Pharmaceuticals will hold its Q4 2024 earnings call on March 10, 2025, at 4:30 PM ET, featuring key executives and analysts from various firms.
The earnings call provides insights into Verrica's financial performance and future outlook, impacting stock valuation and investor sentiment on potential growth and risks.
The company reported a 12.3% sequential growth in YCANTH® dispensed applicator units in Q4'24, alongside a notable reduction in operating expenses.
The 12.3% growth in YCANTH® sales alongside reduced operating expenses indicates improved profitability and operational efficiency, likely boosting investor confidence and stock performance.
Verrica Pharmaceuticals (VRCA) reported a quarterly loss of $0.24 per share, better than the expected loss of $0.25, and improved from a loss of $0.48 per share a year prior.
Verrica's smaller quarterly loss than expected signals potential operational improvement, which may boost investor confidence and influence stock performance.
Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) will host a conference call and live webcast on March 3, 2025, at 4:30 p.m. to discuss developments in its dermatology therapeutics.
Verrica Pharmaceuticals’ conference call may provide crucial updates on drug development and financial performance, influencing stock price and investor sentiment.
Verrica Pharmaceuticals Inc. (VRCA) Expected to Beat Earnings Estimates: Should You Buy?
17 days agoVerrica Pharmaceuticals (VRCA) is expected to report strong earnings due to favorable conditions. Investors should anticipate key expectations ahead of the upcoming report.
Verrica Pharmaceuticals (VRCA) is expected to outperform earnings estimates, signaling potential stock price appreciation and increased investor confidence.
Verrica Pharmaceuticals to Participate in the TD Cowen 45th Annual Health Care Conference in Boston
19 days agoVerrica Pharmaceuticals (Nasdaq: VRCA) will have CEO Jayson Rieger participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference in Boston.
Verrica's CEO speaking at a major health conference highlights company visibility and potential investor interest, signaling developments in its dermatology pipeline that could impact stock performance.
Frequently Asked Questions About VRCA Stock
What is Verrica Pharmaceuticals Inc.'s (VRCA) stock forecast for 2025?
Based on our analysis of 9 Wall Street analysts, Verrica Pharmaceuticals Inc. (VRCA) has a median price target of $3.00. The highest price target is $5.00 and the lowest is $2.00.
Is VRCA stock a good investment in 2025?
According to current analyst ratings, VRCA has 2 Buy ratings, 4 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.54. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for VRCA stock?
Wall Street analysts predict VRCA stock could reach $3.00 in the next 12 months. This represents a 458.7% increase from the current price of $0.54. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Verrica Pharmaceuticals Inc.'s business model?
Verrica Pharmaceuticals operates in the pharmaceutical industry, focusing on niche dermatological products. The company generates revenue through the development and commercialization of its proprietary drug-device combination, VP-102, aimed at treating skin conditions that lack FDA-approved treatments, thereby addressing unmet medical needs in dermatology.
What is the highest forecasted price for VRCA Verrica Pharmaceuticals Inc.?
The highest price target for VRCA is $5.00 from at , which represents a 831.1% increase from the current price of $0.54.
What is the lowest forecasted price for VRCA Verrica Pharmaceuticals Inc.?
The lowest price target for VRCA is $2.00 from Gregory Renza at RBC Capital, which represents a 272.4% increase from the current price of $0.54.
What is the overall VRCA consensus from analysts for Verrica Pharmaceuticals Inc.?
The overall analyst consensus for VRCA is neutral. Out of 9 Wall Street analysts, 2 rate it as Buy, 4 as Hold, and 0 as Sell, with a median price target of $3.00.
How accurate are VRCA stock price projections?
Stock price projections, including those for Verrica Pharmaceuticals Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
